| Adjusted OR | 95 % CI | P-value | |
---|---|---|---|---|
Age | <65 | reference | Â | Â |
 | 65–74 | 1.267 | 1.127–1.425 | <0.0001 |
 | ≥75 | 1.330 | 1.199–1.475 | <0.0001 |
Male | 0.982 | 0.922–1.046 | 0.568 | |
NYHA | I | reference | Â | Â |
 | II | 1.354 | 1.179–1.556 | <0.0001 |
 | III | 1.548 | 1.351–1.774 | <0.0001 |
 | IV | 1.627 | 1.416–1.869 | <0.0001 |
CCI | 1.087 | 1.065–1.108 | <0.0001 | |
LOS | 0.997 | 0.995–0.998 | <0.0001 | |
BMI | 0.972 | 0.964–0.979 | <0.0001 | |
Hospital volume | 1.000 | 1.000–1.000 | 0.932 | |
ACEs or ARBs | 0.749 | 0.703–0.798 | <0.0001 | |
Beta blockers | 1.225 | 1.149–1.306 | <0.0001 | |
Ca channel blockers | 0.834 | 0.776–0.896 | <0.0001 | |
Digitalis | 0.935 | 0.847–1.033 | 0.185 | |
Loop diuretics | 1.286 | 1.187–1.394 | <0.0001 | |
Thiazide | 1.280 | 1.145–1.431 | <0.0001 | |
Spironolactone | 0.795 | 0.743–0.851 | <0.0001 | |
Nitrates | 1.405 | 1.302–1.516 | <0.0001 |